NoteSzHD – "New therapy in psychotic disorders and Huntington's disease with special focus on cognitive deficits" .
– the project received co-financing from the National Centre for Research and Development in the amount of PLN 26,730,836 under THE PROGRAMME OF SCIENTIFIC RESEARCH AND DEVELOPMENT entitled STRATEGMED “PROPHYLAXYS AND TREATMENT OF DISEASES OF AFFLUENCE”
The project is being implemented by Celon Pharma in collaboration with five scientific partners: the Nencki Institute of Experimental Biology in the Polish Academy of Sciences, the Mossakowski Medical Research Centre
in the Polish Academy of Sciences, Institute of Pharmacology of the Polish Academy of Sciences, the Medical University of Lodz and the Poznan University of Medical Sciences. Celon Pharma is responsible for key activities associated with the development of the drug. The tasks of the remaining members of the consortium consist in exploration of mechanisms of action of phosphodiesterase 10A inhibitors (PDE10A).
Celon Pharma has conducted work on innovative PDE10A inhibitors since 2013. Additional support and interest from the scientific community is an opportunity to accelerate the pace of works on the drug to be used is psychotic disorders and Huntington's disease and to make the therapy available to patients.
Total cost of the STRATEGMED project::PLN 40 279 820